甲福明通过调节JNK通路和抑制PANOPTOSIS机制减轻小鼠肌肉心脏缺血-再输液损伤
Biao Hou1,2, Xuejian Hou1, Liyue Zhang3
1Coronary Artery Disease Surgical Center, Capital Medical University Affiliated Anzhen Hospital, Beijing, China.
Cardiovascular therapeutics
|October 15, 2025
概括
甲福明通过调节JNK通路和抑制PANoptosis来保护心脏免受缺血-再输液损伤. 这种常见的糖尿病药物显示出作为心肌梗塞心脏保护疗法的前景.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 心肌缺血-再输血损伤 (MIRI) 在再输血后加剧心脏损伤.
- 甲胺 (Met) 是一种抗糖尿病药物,通过抗炎,抗瘤和代谢调节表现出心脏保护作用.
- 这项研究重点关注梅特福林对MIRI中JNK通路和PANoptosis的影响.
研究的目的:
- 在大鼠MIRI模型中研究梅特福林的心脏保护作用.
- 阐明甲胺对c-Jun N-终端激酶 (JNK) 途径的调制.
- 确定梅特福林在抑制PANoptosis机制中的作用.
主要方法:
- 三四醇化物 (TTC) 和小麦胚芽聚氨酸 (WGA) 染色评估了心肌梗塞和高.
- ELISA测量了血清损伤标志物和炎症性细胞因子.
- 免疫光学和西欧斑点评价了PANoptosis和JNK通路的参与.
主要成果:
- 甲胺显著减少了心肌损伤区域和心脏病发作的大小.
- 甲福明降低了心脏生物标志物 (c-TnI,CK-MB,LDH),炎症性细胞因子 (IL-6,TNF-α) 和活性氧物种 (ROS) 的血清水平.
- 甲胺通过抑制JNK酸化和降低ROS减弱了MIRI诱导的PANoptosis,这种效应被 anisomycin逆转.
结论:
- 梅特福林在MIRI中的心脏保护作用通过调节JNK通路和抑制PANoptosis进行调节.
- 梅特福明显示出作为心肌缺血-再输液损伤的治疗剂的潜力.
- 准JNK通路对于美特福林在MIRI中的保护作用至关重要.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
583
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
583
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
932
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
932
01:23Dipeptidyl Peptidase 4 Inhibitors
587
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
587